This week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone marrow diseases. The European Commission approved AbbVie’s ABBV immunology medicine, Skyrizi for its third indication, Crohn’s disease, in Europe. GSK GSK has begun the process to withdraw its approved multiple myeloma drug, Blenrep from the U.S. market.

Recap of the Week’s Most Important Stories

Merck to Buy Imago BioSciences: Merck announced a definitive agreement to acquire Imago BioSciences for $36.00 per share in cash for an approximate total equity value of $1.35 billion. The acquisition of Imago Biosciences is expected to strengthen Merck’s hematology portfolio by adding Imago’s lead candidate, bomedemstat. Bomedemstat, an oral LSD1 inhibitor, is being evaluated in multiple mid-stage clinical studies for treating bone marrow diseases like essential thrombocythemia, myelofibrosis  and polycythemia vera. The transaction is expected to be completed by first-quarter 2023.

Merck’s Keytruda combined with chemotherapy showed statistically significant improvement in overall survival as a first-line treatment of HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma when compared to those who were treated with chemotherapy alone. Patients who were administered Keytruda plus chemotherapy also showed meaningful improvements in progression-free survival and overall response rate. Keytruda is already approved in combination with Roche’s Herceptin (trastuzumab) and chemotherapy under the accelerated pathway for first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma based on data from the phase III KEYNOTE-811 study.

AbbVie’s Skyrizi Gets EU Nod for Crohn’s Disease: The European Commission approved AbbVie’s Skyrizi (risankizumab) to treat moderate-to-severe Crohn’s disease (“CD”). CD is the third approved indication for Skyrizi in Europe. In the United States, Skyrizi was approved for CD in June. Skyrizi is already approved in the European Union, the United States and some other countries for two other indications — plaque psoriasis and active psoriatic arthritis.

The FDA accepted and granted priority review to AbbVie and partner Genmab’s biologics license application (BLA) seeking approval for epcoritamab for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. In the EU too, a marketing authorization application seeking approval for epcoritamab for relapsed/refractory diffuse large B-cell lymphoma — a major subtype of LBCL — after two or more lines of systemic therapy, was validated by the European Medicines Agency in October. The BLA is supported by data from the LBCL cohort of phase I/II study, EPCORE NHL-1 evaluating subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell NHL, including LBCL.